180 Life Sciences (ATNF) has shared an update.
On May 7, 2024, 180 Life Sciences Corp. underwent significant executive changes, with CEO Dr. James N. Woody and Chief Scientific Officer Dr. Jonathan Rothbard resigning. Woody’s separation agreement included a cash payment, stock shares, and potential future bonuses contingent on company performance, with specific conditions for forfeiture. Rothbard’s departure resulted in a cash payout and a short-term consulting role. Blair Jordan transitioned from Board member to Interim CEO with an associated consulting agreement that includes compensation and a bonus structure. Additionally, the Board established indemnity agreements for directors and officers, ensuring legal protection and expense advancement consistent with Delaware law.
See more data about ATNF stock on TipRanks’ Stock Analysis page.
